Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) EBITDA Margin (2016 - 2017)

Historic EBITDA Margin for Bone Biologics (BBLG) over the last 2 years, with Q4 2017 value amounting to 89.83%.

  • Bone Biologics' EBITDA Margin changed N/A to 89.83% in Q4 2017 from the same period last year, while for Dec 2017 it was 59.38%, marking a year-over-year decrease of 19182500.0%. This contributed to the annual value of 137.01% for FY2021, which is 543500.0% up from last year.
  • Bone Biologics' EBITDA Margin amounted to 89.83% in Q4 2017.
  • Bone Biologics' 5-year EBITDA Margin high stood at 2936.14% for Q1 2016, and its period low was 206.36% during Q2 2017.